Stock Ratings / Health Care / BNR / dividends

KEQU (70) SERA (40) XGN (31) TLSI (34) ⌘ Pro Terminal →

Burning Rock Biotech Limited (BNR) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is BNR trading relative to its 50-day, 200-day, and 52-week technical levels?

BNR last traded at $11.05 (-9.87% on volume of 29,816 shares), positioning the stock -16.54% below its 50-day simple moving average ($13.24) and -32.54% below its 200-day simple moving average ($16.38). Across its 52-week range of $6.79 to $41.72, BNR sits at the 12.2% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.67 to $12.43).

Q: Does BNR pay a dividend and is it safe?

Burning Rock Biotech Limited (BNR) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$11.05 -9.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.83

Burning Rock Biotech Limited (BNR) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $116.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BNR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Burning Rock Biotech Limited (NASDAQ: BNR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $11.05 (-9.87% 1D, market cap $116.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNR ranks #1002 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BNR compare to KEQU and SERA in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), BNR carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 74.7%, and ROIC of -35.0%. By comparison, KEQU (Kewaunee Scientific Corporation) holds a B- grade (70/100 RQD, P/E 10.1x, ROIC 16.7%, cap $97.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNR?

▼

Per BNR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792267), Burning Rock Biotech Limited generated $77.2M in revenue (+9.2% YoY), -$7.9M in net income, and -$4.8M in free cash flow against $117.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.83 (-1.97%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-15.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY BNR SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (35% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (26% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.49-16.7% Next Q

Q2 (-2Q)

Grade E$12.90-8.4% Next Q

Q3 (-1Q)

Grade E$11.82-6.5% Next Q

Current

Grade E$11.05-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BNR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BNR currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.24) and Max Pain ($11.60) forces dealer call-delta covering toward $43.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BNR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.7% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,408

Est. Year-10 Shareholder Yield: $104/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.2K

Yr 2

$11.8K

Yr 3

$12.5K

Yr 4

$13.2K

Yr 5

$13.9K

Yr 6

$14.7K

Yr 7

$15.6K

Yr 8

$16.5K

Yr 9

$17.4K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNR)

✓Walkthrough of BNR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BNR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.00%▼ SUPPORT BREAKDOWN

2026-10-30O $10.51H $11.05L $10.29C $11.05VOL 12.2K

RES: $22.54SUP: $12.98SMA50: $13.24SMA200: $16.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BNR Butterfly Map → + Track BNR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BNR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BNR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BNR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNR)

Health Care Rank #1002 of 1016 ⚔️ KEQU vs BNR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BNR vs. KEQU, SERA, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Burning Rock Biotech Limited (BNR) ranks #1002 by composite RQD confidence (23/100, grade E) and #639 by equity capitalization ($116.5M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with BNR at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BNR ACTIVE Burning Rock Biotech Limited	E	23/100	—	74.7%	-35.0%	-9.87%	$116.5M	Benchmark Subject
KEQU Kewaunee Scientific Corporation	B-	70/100	10.1x	28.5%	16.7%	-3.48%	$97.0M	/kequ-vs-bnr →
SERA Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-bnr →
XGN Exagen Inc.	E	31/100	—	58.3%	-35.0%	+3.57%	$210.8M	/xgn-vs-bnr →
TLSI TriSalus Life Sciences Inc.	E	34/100	—	84.6%	-35.0%	-1.78%	$237.7M	/tlsi-vs-bnr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001792267

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Burning Rock Biotech Limited (BNR) reported GAAP revenue of $77.2M (+9.2% vs. FY2024 revenue of $70.7M , and +1.9% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$4.1M, and free cash flow of -$4.8M (+64.0% YoY). On the balance sheet, BNR closed FY2025 with $117.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$77.2M	-$7.9M	-$4.1M	-$4.8M	$117.3M	—
FY2024 (FY)	2024-12-31	$70.7M	-$47.5M	-$12.6M	-$13.4M	$121.3M	—
FY2023 (FY)	2023-12-31	$75.7M	-$92.1M	-$36.0M	-$36.0M	—	—

3. BNR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BNR compare to KEQU and SERA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BNR?

Where is BNR trading relative to its 50-day, 200-day, and 52-week technical levels?

BNR last traded at $11.05 (-9.87% on volume of 29,816 shares), positioning the stock -16.54% below its 50-day simple moving average ($13.24) and -32.54% below its 200-day simple moving average ($16.38). Across its 52-week range of $6.79 to $41.72, BNR sits at the 12.2% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.67 to $12.43).

BNR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BNR pay a dividend and is it safe?

Burning Rock Biotech Limited (BNR) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BNR RQD Cockpit BNR 12M Forecast BNR Earnings & Move BNR Dividends & DRIP BNR Insiders & 13F BNR Whale Options BNR Profit Sankey BNR News & Why